insights_auto
Why is 4507 down 2.23%?
Dive Deeperchevron_right
4507:TYO
Shionogi & Co Ltd
JP¥ 2,788.50
arrow_downward
-2.23%(-63.50) 1D
10-р сарын 2, 13:04:29 (GMT+9) · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4507...
Open
JP¥ 2,812
High
JP¥ 2,832
Low
JP¥ 2,766
Mkt. cap
2.48ИН
Avg. vol.
2.58 сая
Volume
1.22 сая
Dividend
2.55%
Quarterly dividend
JP¥ 18
Ex-dividend date
2026 оны 9-р сарын 29
P/E ratio
9.01
52-wk high
JP¥ 3,758
52-wk low
JP¥ 2,392
EPS
JP¥ 310
Shares outstanding
314.50 сая
No. of employees
6 мян
Open
JP¥ 2,812
High
JP¥ 2,832
Low
JP¥ 2,766
Mkt. cap
2.48ИН
Avg. vol.
2.58 сая
Volume
1.22 сая
Dividend
2.55%
Quarterly dividend
JP¥ 18
Ex-dividend date
2026 оны 9-р сарын 29
P/E ratio
9.01
52-wk high
JP¥ 3,758
52-wk low
JP¥ 2,392
EPS
JP¥ 310
Shares outstanding
314.50 сая
No. of employees
6 мян
News stories
From web sources and news partners
TradingView
·
17 минутын өмнө
Moderna to join Nasdaq-100, replacing Warner Bros. Discovery
Simply Wall Street
·
25 минутын өмнө
Axon Enterprise (AXON) Circles A Public Safety Deal As Sale Talks Emerge
Yahoo Finance
·
1 цагийн өмнө
Dow, S&P 500, Nasdaq Futures Rise Ahead Of Key Jobs Report: NKE, NFLX, BABA, XRPN Stocks In Focus
MarketWatch
·
7 цагийн өмнө
The stock market is anything but normal right now — and these charts show it
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees6.22 мян
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com